JAMA Surg. 2014 May;149(5):482-5. doi: 10.1001/jamasurg.2013.3643.
Circulating tumor cells (CTCs) disseminate from the primary tumor and travel through the bloodstream and lymphatic system. The detection of and/or increase in the number of CTCs during a patient’s clinical course may be a harbinger of forthcoming overt metastasis. We aimed to examine the impact of 2 different surgical techniques, standard (ST) pancreaticoduodenectomy (PD) and no-touch isolation (NT) PD, on tumor behavior and outcome in patients with pancreatic cancer by using CTCs as biomarkers. In this pilot study, patients were randomized to either ST-PD (n = 6) or NT-PD (n = 6). Intraoperatively, blood samples were taken from the portal vein for measurement of CTCs before and immediately after removal of the tumor. An increase in CTCs was seen in 5 of 6 patients (83%) with ST-PD but no patients with NT-PD (P = .003). In the ST-PD and NT-PD groups, median overall survival was 13.0 and 16.7 months, respectively (P = .33); there was no difference in disease-free survival (P = .42). The use of NT-PD significantly reduced the number of CTCs in the portal vein with no benefit in survival outcomes compared with ST-PD, although more extensive studies are required.
循环肿瘤细胞(CTCs)从原发性肿瘤扩散,通过血液和淋巴系统传播。在患者的临床过程中,CTCs 的检测和/或数量增加可能是即将发生显性转移的先兆。我们旨在通过使用 CTCs 作为生物标志物,检查两种不同的手术技术(标准(ST)胰十二指肠切除术(PD)和无接触隔离(NT)PD)对胰腺癌患者肿瘤行为和结果的影响。在这项初步研究中,患者被随机分为 ST-PD(n=6)或 NT-PD(n=6)组。术中,从门静脉采集血液样本,在切除肿瘤前后测量 CTCs。在 6 名接受 ST-PD 的患者中,有 5 名(83%)患者的 CTCs 增加,但没有接受 NT-PD 的患者(P=0.003)。在 ST-PD 和 NT-PD 组中,中位总生存期分别为 13.0 个月和 16.7 个月(P=0.33);无疾病生存期无差异(P=0.42)。与 ST-PD 相比,使用 NT-PD 可显著减少门静脉中 CTCs 的数量,但对生存结果没有益处,尽管还需要更多的研究。